ASK1 Inhibitor Compounds With Modular Substituent Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new compounds that can inhibit the activity of Apoptosis Signal-regulating Kinase 1 (ASK1) to address a range of diseases including neurodegenerative, cardiovascular, inflammatory, and metabolic disorders, as well as organ damage following ischemia and reperfusion.
Innovation Solution
Development of compounds represented by specific chemical formulas (I, II, III, IV) and their pharmaceutically acceptable salts, which act as ASK1 inhibitors to modulate its activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing ASK1 inhibitors are used, then ASK1 activity is inhibited, but new compounds with improved efficacy and safety profiles are needed
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structures of ASK1 inhibitors through varying substituents at multiple positions (R1-R6 groups, aromatic ring substitutions, heteroatom replacements). This generates a series of analogs with different pharmacological properties, addressing the need for compounds with improved efficacy and safety profiles while maintaining ASK1 inhibition activity.
Solution Approach 2:
The patent segments the inhibitor molecule into distinct functional regions (core structure with separable substituent groups R1-R6). This modular approach allows independent optimization of different molecular regions to enhance binding affinity, selectivity, and pharmacokinetic properties, enabling the development of next-generation ASK1 inhibitors with improved characteristics.
2Adaptability or versatility
If ASK1 inhibition is achieved, then therapeutic benefits for various disorders are provided, but comprehensive coverage of multiple disease types is required
Solution Approach 1:
The patent achieves universality by developing ASK1 inhibitors with broad therapeutic applicability across multiple disease categories including neurodegenerative disorders, cardiovascular diseases, inflammatory conditions, metabolic disorders, and organ damage. The compounds are designed to target ASK1's central role in stress-responsive signaling pathways that are common to these diverse conditions, enabling a single inhibitor class to address multiple disease types.
Data Source
AI summary
Provided are compounds of Formula (I):including compounds of Formulas (II), (III) and (IV), wherein X, R1, R2, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).